Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Ovarian Cancer | What I Tell My Patients: Integrating New Research Information into Current Clinical Care — Ovarian Cancer

1:32:21
 
Share
 

Manage episode 421982171 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Featuring perspectives from Ms Courtney Arn, Dr Floor J Backes, Dr Kathleen N Moore and Ms Jaclyn Shaver, including the following topics:

  • Introduction: The Incidence, Pathogenesis and Prognosis of Ovarian Cancer (0:00)
  • Genetic Testing for Newly Diagnosed Advanced Ovarian Cancer (11:01)
  • The Role of PARP Inhibitor Maintenance for Newly Diagnosed Advanced Ovarian Cancer (19:02)
  • Side Effects Associated with PARP Inhibitors (29:58)
  • Dosing, Adherence and Other Issues with PARP Inhibitors for Ovarian Cancer (48:29)
  • The Potential Role of PARP Inhibitors in Combination with Anti-PD-1/PD-L1 Antibodies for Advanced Ovarian Cancer Management (54:11)
  • PARP Inhibitors for Relapsed/Refractory Ovarian Cancer (1:00:36)
  • The Current Role of Mirvetuximab Soravtansine for Ovarian Cancer Treatment (1:07:14)
  • Toxicities with Mirvetuximab Soravtansine (1:11:53)
  • The Incidence and Management of HER2-Positive Ovarian Cancer (1:18:18)

NCPD information and select publications

  continue reading

1412 episodes

Artwork
iconShare
 
Manage episode 421982171 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Featuring perspectives from Ms Courtney Arn, Dr Floor J Backes, Dr Kathleen N Moore and Ms Jaclyn Shaver, including the following topics:

  • Introduction: The Incidence, Pathogenesis and Prognosis of Ovarian Cancer (0:00)
  • Genetic Testing for Newly Diagnosed Advanced Ovarian Cancer (11:01)
  • The Role of PARP Inhibitor Maintenance for Newly Diagnosed Advanced Ovarian Cancer (19:02)
  • Side Effects Associated with PARP Inhibitors (29:58)
  • Dosing, Adherence and Other Issues with PARP Inhibitors for Ovarian Cancer (48:29)
  • The Potential Role of PARP Inhibitors in Combination with Anti-PD-1/PD-L1 Antibodies for Advanced Ovarian Cancer Management (54:11)
  • PARP Inhibitors for Relapsed/Refractory Ovarian Cancer (1:00:36)
  • The Current Role of Mirvetuximab Soravtansine for Ovarian Cancer Treatment (1:07:14)
  • Toxicities with Mirvetuximab Soravtansine (1:11:53)
  • The Incidence and Management of HER2-Positive Ovarian Cancer (1:18:18)

NCPD information and select publications

  continue reading

1412 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide